NEULAND
WHERE OPPORTUNITY BECOMES REALITY

Neuland Laboratories Limited
Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 30211600 / 23551081
Fax: 040 30211602
Email: neuland@neulandlabs.com
www.neulandlabs.com

May 8, 2018

To
B S E Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

Scrip Code: 524558

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 001

Scrip Code: NEULANDLAB
Series: EQ

Dear Sirs,

Results Release and Earnings Call Notice

We refer to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 and enclose a copy of the Q4 FY 2018 Earnings Call details, for your information and records.

Thanking you,

Yours faithfully,
For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Neuland Laboratories Limited's Q4 & FY 2017-18 Results Conference Call

At 17:30 hrs. IST on May 11, 2018

Neuland Laboratories Limited will announce its results for the fourth quarter and full-year ended March 31, 2018 on May 11, 2018. The results will also be made available on the website of the Company, www.neulandlabs.com.

Following the announcement, the management of the Company will host an Earnings Call on the **same day** at **17:30 hrs**. The details of the earnings call are:

Date: May 11, 2018 Time: 17:30 Hrs.

Dial-in Number: +91 22 6280 1107 / +91 22 7115 8008

You can also click here for the diamond pass and calendar invite to your inbox

Other Numbers:

Local Access Number

+91-7045671221 (Available all over India)

International Toll-Free Number

USA - 18667462133 | UK - 08081011573 | Singapore - 8001012045 | Hong Kong - 800964448

About Neuland Laboratories Limited (BSE:524558, NSE: NEULANDLAB)

For over 34 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs, and it has filed around 53 U.S. drug master files (USDMFs) and a total of around 650 Regulatory filings in the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), Health Canada, CFDA (China), ISO 9001, ISO14001, OHSAS18001 and ISO 27001.

For more information, visit www.NeulandLabs.com.

For Queries:

Neuland: ir@neulandlabs.com or **Diwakar Pingle:** dpingle@christensenir.com